BRPI0413745A - horário mde dosagem para agentes anticancerìgenos erbb2 - Google Patents

horário mde dosagem para agentes anticancerìgenos erbb2

Info

Publication number
BRPI0413745A
BRPI0413745A BRPI0413745-0A BRPI0413745A BRPI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A
Authority
BR
Brazil
Prior art keywords
erbb2
mammal
relates
anticancer agents
dosing schedule
Prior art date
Application number
BRPI0413745-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Roe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413745A publication Critical patent/BRPI0413745A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0413745-0A 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2 BRPI0413745A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
BRPI0413745A true BRPI0413745A (pt) 2006-10-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413745-0A BRPI0413745A (pt) 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20080014144A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) * 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007059106A2 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
ATE446294T1 (de) 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
RU2429014C2 (ru) * 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
KR20080108516A (ko) * 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
NZ580866A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating brain cancer
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) * 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
JP6183471B2 (ja) * 2014-01-31 2017-08-23 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
AP2004003058A0 (en) * 2001-12-12 2004-06-30 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth.
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
WO2004046101A2 (en) * 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток

Also Published As

Publication number Publication date
SG135193A1 (en) 2007-09-28
MXPA06001989A (es) 2006-05-17
US20050119288A1 (en) 2005-06-02
RU2328287C2 (ru) 2008-07-10
AU2004264726A1 (en) 2005-02-24
RU2006102125A (ru) 2007-09-27
IL173127A0 (en) 2006-06-11
CO5670356A2 (es) 2006-08-31
NO20061252L (no) 2006-05-16
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
KR20080014144A (ko) 2008-02-13
WO2005016347A1 (en) 2005-02-24
CA2536140A1 (en) 2005-02-24
CN1838959A (zh) 2006-09-27
EP1658080A1 (en) 2006-05-24
ZA200600517B (en) 2007-02-28
KR20060037447A (ko) 2006-05-03
AR045268A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
Argyriou et al. A review on oxaliplatin-induced peripheral nerve damage
DIONNE et al. Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine
Kosharskyy et al. Intravenous infusions in chronic pain management
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0110420A (pt) Agonistas muscarìnicos
George et al. Review of nonopioid multimodal analgesia for surgical and trauma patients
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
Martınez-Raga et al. Add-on gabapentin in the treatment of opiate withdrawal
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
Kaczmarzyk et al. Preemptive effect of ketoprofen on postoperative pain following third molar surgery. A prospective, randomized, double-blinded clinical trial
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
JP2016507493A5 (enExample)
BRPI0607536A2 (pt) tratamento de dor
Marri Adjuvant agents in regional anaesthesia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.